低ヒスタミンに基づく改良地中海食の多発性硬化症への効果 (HistaMed-MS)
多発性硬化症における低ヒスタミン修飾地中海食の無作為化比較試験:食事介入が臨床所見、血漿ヒスタミン、酸化ストレスに及ぼす影響
This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS). The study will compare three groups: a low-histamine modified Mediterranean diet, a traditional Mediterranean diet, and a control group without dietary intervention. The main outcomes include clinical measures such as disability status, fatigue, and quality of life, as well as blood markers including plasma histamine, diamine oxidase concentration, total antioxidant capacity, and oxidative stress indicators. The goal is to determine whether reducing dietary histamine within a Mediterranean diet pattern provides additional benefits beyond a traditional Mediterranean diet in improving symptoms and biological markers related to inflammation and oxidative stress in RRMS.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and a leading cause of neurological disability in young adults. Current immunomodulatory treatments have important side effects and do not fully address symptoms or quality of life, highlighting the need for complementary strategies such as targeted dietary interventions. The Mediterranean diet is one of the most promising patterns because of its anti-inflammatory and antioxidant properties and has been associated with reduced fatigue, improved quality of life, and potential benefits on disability in people with MS. However, some components of the traditional Mediterranean diet, such as certain fish, aged cheeses, fermented products, tomatoes, and citrus fruits, are relatively high in histamine. Histamine is a biogenic amine that may influence neuroinflammation and blood-brain barrier permeability, and diets that lower histamine intake have shown benefits in conditions like migraine and gastrointestinal dysfunction, which are common in MS. This study was designed to explore whether a low histamine-based modified Mediterranean diet can optimize the benefits of the Mediterranean pattern in relapsing-remitting MS (RRMS).
The trial is a three-arm, parallel-group, randomized controlled clinical study in adults with RRMS. Participants are randomly assigned to one of three groups: (1) a low histamine-based modified Mediterranean diet, which maintains the core principles of the Mediterranean pattern while restricting foods known to be high in histamine or to promote histamine release; (2) a traditional Mediterranean diet without specific histamine-related restrictions; or (3) a control group that does not receive a structured dietary intervention. The intervention focuses on high intake of fresh vegetables and fruits, legumes, whole grains, olive oil, and appropriate fish options, while the modified diet group additionally limits aged cheeses, processed meats, fermented foods, vinegar, fish and seafood, and selected vegetables and fruits that are high in histamine. This design allows direct comparison of no diet intervention, a well-established Mediterranean pattern, and a targeted low-histamine modification of that pattern.
Clinical outcomes include disability status assessed by the Expanded Disability Status Scale (EDSS), fatigue measured with the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), and health-related quality of life evaluated with the Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire. To investigate potential mechanisms, blood biomarkers are measured, including serum total antioxidant capacity, oxidative stress markers (for example malondialdehyde), plasma histamine levels, and plasma concentration of diamine oxidase (DAO), an enzyme that metabolizes histamine. The primary hypotheses are that both Mediterranean diet interventions will improve fatigue, quality of life, and oxidative stress parameters compared with the control group, and that the low histamine-based modified Mediterranean diet will provide the greatest benefits, particularly in reducing plasma histamine, increasing DAO concentration, and alleviating fatigue and disability scores in RRMS. If confirmed, the findings could support a more targeted dietary approach as a complementary medical nutrition therapy for MS and provide a basis for future interventional studies on histamine metabolism, oxidative stress, and diet in this population.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Elâzığ
-
Elâzığ、Elâzığ、トルコ(Türkiye)、23119
- Firat University Hospital, Neurology Clinic
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 19 to 64 years.
- Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to 2017 McDonald criteria.
- EDSS score < 4.5.
- On stable immunomodulatory treatment for at least 6 months.
- Body mass index (BMI) 18.5-29.9 kg/m².
Exclusion Criteria:
- Relapse and/or corticosteroid treatment within the last 1 month.
- Clinically significant metabolic, progressive, or malignant disease.
- Use of at least 1 g/day fish oil supplementation.
- Insulin-dependent diabetes mellitus.
- Participation in another interventional study.
- Weight loss or gain ≥ 5% in the last 6 months.
- Following a weight-loss diet in the last 2 months.
- Use of oral anticoagulant therapy.
- Presence of eating disorders, alcohol or substance dependence.
- Pregnancy or breastfeeding.
- Inability to comply with dietary intervention according to weekly follow-up assessments.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Low Histamine-Based Modified Mediterranean Diet
Participants receive a low histamine-based modified Mediterranean diet with restriction of high-histamine and histamine-releasing foods while preserving core Mediterranean diet principles. |
Structured dietary program based on the Mediterranean diet with restriction of high-histamine and histamine-releasing foods (e.g., aged cheeses, processed meats, fish and seafood, fermented products, vinegar, some fruits and vegetables); fish is replaced with poultry. |
|
アクティブコンパレータ:Traditional Mediterranean Diet
Participants receive a traditional Mediterranean diet without specific histamine-related restrictions. |
Structured dietary program following a traditional Mediterranean diet rich in vegetables, fruits, whole grains, legumes, olive oil, and fish, without specific histamine-related restrictions. |
|
介入なし:Control (Usual Diet)
Participants continue their usual diet and do not receive a structured dietary intervention. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in neurological fatigue (Neurological Fatigue Index for Multiple Sclerosis [NFI-MS] subscale scores; ranges: physical fatigue 0-24, cognitive fatigue 0-12, diurnal sleep 0-18, nocturnal sleep 0-15; higher scores indicate greater fatigue)
時間枠:Baseline, week 6 and week 12
|
Fatigue will be assessed using the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), a 23-item self-reported questionnaire with four subscales: physical fatigue (8 items), cognitive fatigue (4 items), relief by diurnal sleep or rest (6 items), and abnormal nocturnal sleep and sleepiness (5 items). Items are rated from 0 to 3, each subscale is scored separately (no total score is calculated), and higher scores indicate greater fatigue. The outcome is the change in each subscale score from baseline to week 12 across the three study groups. |
Baseline, week 6 and week 12
|
|
Change in plasma histamine concentration
時間枠:From baseline to 12 weeks
|
Plasma histamine will be measured in fasting EDTA plasma by competitive ELISA. The outcome is the change in plasma histamine concentration (ng/mL) between baseline and the end of the intervention. |
From baseline to 12 weeks
|
|
Change in plasma diamine oxidase (DAO) concentration
時間枠:From baseline to 12 weeks
|
Plasma diamine oxidase (DAO), a key enzyme of histamine metabolism, will be measured in fasting EDTA plasma by sandwich ELISA. The outcome is the change in plasma DAO concentration (ng/mL) between baseline and the end of the intervention. |
From baseline to 12 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in disability status (Expanded Disability Status Scale [EDSS]; scale range: 0-10; higher scores indicate greater disability)
時間枠:From baseline to 12 weeks
|
Disability will be assessed using the Expanded Disability Status Scale (EDSS). The outcome is the change in EDSS score from baseline to the end of the intervention. |
From baseline to 12 weeks
|
|
Change in health-related quality of life (Multiple Sclerosis Quality of Life-54 [MSQOL-54]; scale range: 0-100 for subscale and composite scores; higher scores indicate better health-related quality of life)
時間枠:From baseline to 12 weeks
|
Health-related quality of life will be assessed using the MSQOL-54 questionnaire. The outcome is the change in MSQOL-54 scores from baseline to the end of the intervention. |
From baseline to 12 weeks
|
|
Change in serum total antioxidant capacity
時間枠:From baseline to 12 weeks
|
Serum total antioxidant capacity will be measured to evaluate antioxidant status. The outcome is the change in serum total antioxidant capacity between baseline and the end of the intervention. |
From baseline to 12 weeks
|
|
Change in oxidative stress markers (e.g., malondialdehyde)
時間枠:From baseline to 12 weeks
|
Oxidative stress will be assessed using markers such as malondialdehyde (MDA). The outcome is the change in oxidative stress markers between baseline and the end of the intervention. |
From baseline to 12 weeks
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Murat Gönen, Prof. Dr.、Firat University Faculty of Medicine
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 2023/03-26
- 223S505 (その他の識別子:The Scientific and Technological Research Council of Turkey (TÜBİTAK))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual participant data underlying the results reported in the publication will be shared, together with the data dictionary.
IPD 共有時間枠
Beginning after publication of the main results.
IPD 共有アクセス基準
Available from the corresponding author upon reasonable request, subject to approval by the institutional ethics committee.
IPD 共有サポート情報タイプ
- ANALYTIC_CODE
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。